Long-Term Eszopiclone Use Beyond 5 Years: Evidence and Recommendations

Introduction to Eszopiclone Use

The American College of Physicians explicitly states that evidence is insufficient to evaluate the balance of benefits and harms of long-term use of pharmacologic treatments in adults with chronic insomnia disorder 1, 2, 3
The FDA has approved eszopiclone and other hypnotics for short-term use only (4-5 weeks) and recommends against extended use without reevaluation 1, 2, 3

The longest controlled trials of eszopiclone extend only to 6-12 months, creating a substantial evidence void for use beyond this timeframe 4

Dementia risk increases with prolonged hypnotic exposure 1, 2, 3
Serious injury and fractures occur more frequently, particularly concerning for older adults 1, 2, 3
Daytime impairment, sleep driving, behavioral abnormalities, and worsening depression are FDA-labeled warnings 1, 2, 3

For patients already taking eszopiclone beyond evidence-supported durations, immediately initiate cognitive behavioral therapy for insomnia (CBT-I) as the evidence-based first-line treatment 5, 3
Assess for underlying or new comorbid conditions that may perpetuate insomnia (depression, anxiety, pain syndromes, sleep apnea, restless legs syndrome) 5
Implement structured tapering protocol, including transition to intermittent dosing (3 nights per week) rather than nightly use, and use as-needed dosing based on actual sleep need 5

Do not continue prescribing without attempting CBT-I, which has moderate-quality evidence for efficacy and facilitates medication discontinuation 5, 3
Do not ignore the 4-5 week FDA approval window as a signal that longer use requires exceptional justification and heightened monitoring 1, 2, 3
Do not assume short-term safety data extrapolates to 5+ years, as observational studies reveal harms not apparent in controlled trials 1, 2, 3